Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol To FDA For Comment

Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) (”Duska”) announced that it has submitted for comment a synopsis of a proposed Phase 3 clinical study for its lead drug, ATPace(TM), to the U.S. Food and Drug Administration’s (the “FDA”) Division of Cardiovascular and Renal Products.

More: continued here

Filed under: Cardiovascular on July 25th, 2008